31 research outputs found
USP22 overexpression fails to augment tumor formation in MMTV-ERBB2 mice but loss of function impacts MMTV promoter activity.
The Ubiquitin Specific Peptidase 22 (USP22), a component of the Spt-Ada-Gcn5 Acetyltransferase (SAGA) histone modifying complex, is overexpressed in multiple human cancers, but how USP22 impacts tumorigenesis is not clear. We reported previously that Usp22 loss in mice impacts execution of several signaling pathways driven by growth factor receptors such as erythroblastic oncogene B b2 (ERBB2). To determine whether changes in USP22 expression affects ERBB2-driven tumorigenesis, we introduced conditional overexpression or deletion alleles of Usp22 into mice bearing the Mouse mammary tumor virus-Neu-Ires-Cre (MMTV-NIC) transgene, which drives both rat ERBB2/NEU expression and Cre recombinase activity from the MMTV promoter resulting in mammary tumor formation. We found that USP22 overexpression in mammary glands did not further enhance primary tumorigenesis in MMTV-NIC female mice, but increased lung metastases were observed. However, deletion of Usp22 significantly decreased tumor burden and increased survival of MMTV-NIC mice. These effects were associated with markedly decreased levels of both Erbb2 mRNA and protein, indicating Usp22 loss impacts MMTV promoter activity. Usp22 loss had no impact on ERBB2 expression in other settings, including MCF10A cells bearing a Cytomegalovirus (CMV)-driven ERBB2 transgene or in human epidermal growth factor receptor 2 (HER2)+ human SKBR3 and HCC1953 cells. Decreased activity of the MMTV promoter in MMTV-NIC mice correlated with decreased expression of known regulatory factors, including the glucocorticoid receptor (GR), the progesterone receptor (PR), and the chromatin remodeling factor Brahma-related gene-1 (BRG1). Together our findings indicate that increased expression of USP22 does not augment the activity of an activated ERBB2/NEU transgene but impacts of Usp22 loss on tumorigenesis cannot be assessed in this model due to unexpected effects on MMTV-driven Erbb2/Neu expression
USP22 lentiviral shRNA vectors.
The Ubiquitin Specific Peptidase 22 (USP22), a component of the Spt-Ada-Gcn5 Acetyltransferase (SAGA) histone modifying complex, is overexpressed in multiple human cancers, but how USP22 impacts tumorigenesis is not clear. We reported previously that Usp22 loss in mice impacts execution of several signaling pathways driven by growth factor receptors such as erythroblastic oncogene B b2 (ERBB2). To determine whether changes in USP22 expression affects ERBB2-driven tumorigenesis, we introduced conditional overexpression or deletion alleles of Usp22 into mice bearing the Mouse mammary tumor virus-Neu-Ires-Cre (MMTV-NIC) transgene, which drives both rat ERBB2/NEU expression and Cre recombinase activity from the MMTV promoter resulting in mammary tumor formation. We found that USP22 overexpression in mammary glands did not further enhance primary tumorigenesis in MMTV-NIC female mice, but increased lung metastases were observed. However, deletion of Usp22 significantly decreased tumor burden and increased survival of MMTV-NIC mice. These effects were associated with markedly decreased levels of both Erbb2 mRNA and protein, indicating Usp22 loss impacts MMTV promoter activity. Usp22 loss had no impact on ERBB2 expression in other settings, including MCF10A cells bearing a Cytomegalovirus (CMV)—driven ERBB2 transgene or in human epidermal growth factor receptor 2 (HER2)+ human SKBR3 and HCC1953 cells. Decreased activity of the MMTV promoter in MMTV-NIC mice correlated with decreased expression of known regulatory factors, including the glucocorticoid receptor (GR), the progesterone receptor (PR), and the chromatin remodeling factor Brahma-related gene-1 (BRG1). Together our findings indicate that increased expression of USP22 does not augment the activity of an activated ERBB2/NEU transgene but impacts of Usp22 loss on tumorigenesis cannot be assessed in this model due to unexpected effects on MMTV-driven Erbb2/Neu expression.</div
Decreased expression of SAGA components, ERBB2, and ERBB3 upon deletion of <i>Usp22</i> in mammary gland epithelial cells (MECs) collected from 100-day old NIC mice.
(A) Immunoblot analyses showed decreased levels of USP22, GCN5, ATXN7L3, ERBB2, phosphor-ERBB2 and ERBB3 proteins in MECs collected from Usp22FL/FL- NIC mice compared to Usp22+/+—NIC and Usp22FL/+—NIC mice. Despite the sharp decrease in the levels of the receptors, the levels of phosphorylated AKT and phosphorylated ERK show an increase. HSP70, HSP90AB1 and HSP90 protein levels were not affected when analyzed by western blotting in the same lysates. n = 3 for each group. (B, C) qRT-PCR analysis of total RNA collected from Usp22FL/FL- NIC MECs confirmed that mRNA levels of Usp22 and Erbb2 were drastically decreased compared to Usp22+/+- NIC. pUsp22 and Erbb2, as determined by two-tailed unpaired t test. n = 5 for each group. Each sample was measured in triplicate. (D) Immunoblot analyses using lysates from endpoint tumors from Usp22FL/FL- NIC mice showed that levels of USP22, ERBB2, ERBB3, phosphorylated ERK and H2Bub decreased relative to other genotypes, but levels of HSP70, HSP90, HSP90AB1, GCN5 and phosphorylated AKT did not change. n = 3 for each group.</p
Depletion or deletion of <i>USP22</i> in MCF10A cells that stably overexpress ERBB2 did not affect the levels of ERBB2.
(A) Efficient depletion of USP22 by lentiviral shRNA knock down in MCF10A-ERBB2 cells as verified by qRT-PCR analysis. (B) qRT-PCR analysis indicates levels of ERBB2 mRNA did not change upon USP22 shRNA knock down. ns: No statistical significance. (C) Immunoblot analysis of MCF10A-ERBB2 cell lysates showed that ERBB2 protein levels are not changed upon USP22 shRNA knock down. (D) Immunoblot analysis of MCF10A-ERBB2 cell lysates indicate that ERBB2 protein levels are not changed upon USP22 CRISPR/Cas9 knockout. (E). Immunoblot analysis of HER2-positive SKBR3 and HCC1954 cell lysates showed no difference in ERBB2 protein levels upon USP22 shRNA knock down.</p
Validation of high enrichment of epithelial cells vs fibroblasts in lysates from mammary epithelial cells (MECs) collected from 100-day old NIC mice.
Validation of high enrichment of epithelial cells vs fibroblasts in lysates from mammary epithelial cells (MECs) collected from 100-day old NIC mice.</p
Raw images of all western blots presented in Fig 6D.
Raw images of all western blots presented in Fig 6D.</p
Expression levels of ERBB2 and ER⍺ proteins and incidence of lung metastases in <i>Usp22</i> <sup><i>OE/OE</i></sup>- NIC mice.
(A) Immunoblot analyses using lysates from endpoint tumors (n = 3 for each group) showed no difference in the levels of ERBB2 and ER⍺ protein levels upon overexpression of USP22 in Usp22OE/OE- NIC mice. Levels of phosphorylated ERBB2 protein were also unaffected by USP22 overexpression, as well as the levels of phosphorylated AKT, whereas the levels of phosphorylated ERK show a slight decrease. The levels of EMT markers like E-CADHERIN were decreased, and the levels of SLUG were increased in Usp22 OE/OE NIC/+ mice when compared with Usp22+/+- NIC mice. EMT markers including OCCLUDIN, VIMENTIN and TWIST were not significantly affected by USP22 overexpression. (B) Incidence of lung metastasis observed in Usp22+/+-NIC (n = 19), Usp22OE/+-NIC (n = 22) and Usp22OE/OE- NIC (n = 22) mice. (C) Graph of Her2 signaling cascade highlighting key cytosolic effectors analyzed in this study.</p
Delayed tumor formation upon conditional deletion of <i>Usp22</i> in mammary gland epithelial cells in MMTV-NIC mice.
(A) Schematic representation Usp22 floxed mice crossed with MMTV- NIC mice to generate of Usp22FL/FL- NIC progeny. (B) Kaplan-Meier curve showing tumor-free survival of animals, comparing Usp22+/+- NIC (n = 20), Usp22FL/+- NIC (n = 18) and Usp22FL/FL- NIC (n = 21) mice. ***pUsp22+/+- NIC and Usp22FL/FL- NIC were compared. (C-E) Total tumor weight per mouse (C), total tumor volume per mouse (D) and number of tumors per animal (E) measured in Usp22+/+- NIC (n = 11; p = 0.0015), Usp22FL/+- NIC (n = 5; p = 0.0027) and Usp22FL/FL- NIC mice (n = 14; pUsp22FL/FL—NIC mice with Usp22+/+- NIC mice.</p
Raw images of all western blots presented in Fig 4D.
Raw images of all western blots presented in Fig 4D.</p
Raw images of all western blots presented in S1 Fig.
Raw images of all western blots presented in S1 Fig.</p